Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16675
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNeef, Pieter A-
dc.contributor.authorBurrell, Louise M-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorIrving, Louis B-
dc.contributor.authorJohnson, Douglas F-
dc.contributor.authorSteinfort, Daniel P-
dc.date2017-06-13-
dc.date.accessioned2017-06-15T07:35:30Z-
dc.date.available2017-06-15T07:35:30Z-
dc.date.issued2017-09-
dc.identifier.citationInternal Medicine Journal 2017; 47(9): 1043-1050en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16675-
dc.description.abstractBACKGROUND: In patients with chronic obstructive pulmonary disease (COPD) and comorbid cardiovascular disease emerging evidence suggests a benefit in commencing cardioselective beta-blockers. AIM: Our objective was to determine the safety of beta-blocker commencement during hospitalisation for acute exacerbation of COPD. METHODS: A retrospective cohort study of 1,071 patients hospitalised for acute exacerbation of COPD was conducted across two tertiary hospitals over a 12-month period. We identified 36 patients in whom beta-blocker therapy was commenced during admission. Primary outcome of the study was to assess cardiovascular and respiratory adverse events related to the commencement of beta-blocker therapy. RESULTS: The most common indications for beta-blockers were atrial fibrillation (53%) and acute coronary syndrome (36%). Metoprolol was the most commonly prescribed beta-blocker (75%). No patients suffered clinically significant decline of respiratory function following the commencement of a beta-blocker, including worsening respiratory symptoms, oxygen, bronchodilator or ventilation requirements. These results were demonstrable in patients with reversible airways disease and advanced COPD. Only one patient (2.8%) experienced symptomatic hypotension after 48 hours of therapy. CONCLUSION: The commencement of cardio-selective beta-blockers during acute exacerbations of COPD appears to be well-tolerated.en_US
dc.subjectAcute exacerbation of COPDen_US
dc.subjectBeta-blockeren_US
dc.subjectCardiovascular diseaseen_US
dc.subjectChronic obstructive pulmonary diseaseen_US
dc.subjectSafetyen_US
dc.titleCommencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary diseaseen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternal Medicine Journalen_US
dc.identifier.affiliationGeneral Medicineen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationDepartment of Medicine and Cardiology, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Melbourne Health, Parkville, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28608512en_US
dc.identifier.doi10.1111/imj.13518en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-1863-7539en_US
dc.identifier.orcid0000-0001-6481-3391en_US
dc.identifier.orcid0000-0002-7143-7387en_US
dc.type.austinJournal Articleen_US
local.name.researcherBurrell, Louise M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.